Ipamorelin
Ipamorelin (distinguish salt and formulation)
Source type: Human study. Sources checked .
What the cited research examined
A pharmacokinetic study measured ipamorelin and GH responses during intravenous infusion in healthy men.
Intravenous results do not establish subcutaneous kinetics, a general-use schedule, or safety of compounded products.
Reference facts
- Half-life
- Approximately 2 hoursTerminal half-life after a 15-minute intravenous infusion in healthy men. Not a value established for subcutaneous products.
- Human dose range
- Not provided. This reference does not recommend a human dose.
- Administration interval
- Not established by these sources. A half-life is not a dosing schedule.
- Storage
- Product-specific information required. These sources do not establish a storage specification.
Safety context
FDA highlights immune risks and serious intravenous-study adverse events.
Research results and substance listings are not product approvals. The FDA overview distinguishes current Category 2 entries from withdrawn nominations; withdrawal does not establish safety.
Sources and review method
- Healthy-men intravenous pharmacokinetic/pharmacodynamic study
- FDA: bulk substances with potential safety risks (includes withdrawn nominations)
These are bounded summaries of the linked sources, not systematic reviews. An unknown field means that these sources do not establish a general-use value. It does not claim that no other literature exists.
The calculator converts values you provide. The planner organizes entries you choose. Neither tool assesses whether a substance or schedule is appropriate.